Custom-Made cancer vaccine targets leftover disease after surgery
NCT ID NCT06529822
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find and destroy remaining cancer cells. The study will check if the vaccine is safe, can be made in time, and helps clear cancer DNA from the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth
NOT_YET_RECRUITINGOrlando, Florida, 32804, United States
-
Ohio State University
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can switching cancer therapy early extend life in stomach cancer?